-+ 0.00%
-+ 0.00%
-+ 0.00%

Clearmind Medicine posts update on CMND-100 first-in-human trial webinar insights

PUBT·07/13/2026 12:18:06
Listen to the news
Clearmind Medicine posts update on CMND-100 first-in-human trial webinar insights
  • Clearmind Medicine published an update on early real-world insights from its ongoing first-in-human Phase I/IIa CMND-100 trial in alcohol use disorder.
  • Investigators cited a generally positive early impression, citing recruitment progress and no meaningful adverse events or cardiac safety concerns to date.
  • Update highlighted MEAI’s non-hallucinogenic profile as a potential enabler of a simpler outpatient treatment model.
  • Webinar link: Watch the webinar here.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130817PRIMZONEFULLFEED9761076) on July 13, 2026, and is solely responsible for the information contained therein.